GLP-1 drugs and fat loss: does 'metabolic efficiency' hold up?
Quick answer
The stack described combines a monoamine reuptake inhibitor (tesofensine), an NNMT inhibitor (5-amino-1MQ), a REV-ERB agonist (SLUPP-332), and a PPAR-delta agonist (cardarine), none of which are approved for human use and three of which lack any human clinical trial data. Cardarine is of particular concern: its original pharmaceutical developers terminated development after rapid-onset carcinogenicity findings in multiple animal species. No regulatory body has approved any of these compounds for fat loss, and their combined use in humans has no published safety or pharmacokinetic data.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @tonyhuge.official actually say?
Tony Huge pitched four compounds as a superior fat loss stack, calling them "the four horsemen of getting shredded" and claiming they "obliterate fat like nothing else." The four compounds named were tesofensine, 5-amino-1MQ, SLUPP-332, and cardarine (GW501516). Each was assigned a specific role: appetite suppression, lipolysis, metabolic efficiency, and endurance-driven fat oxidation. The framing was conspiratorial: "they don't want you to know about this one." The caption, notably, never mentions these compounds by name, instead describing vague lifestyle principles like "appetite control" and "metabolic efficiency." That gap between the caption and the actual transcript is worth noting.
Does the science back this up?
Partially, but the safety picture is being almost entirely ignored. Tesofensine has genuine Phase 2 trial data. 5-amino-1MQ has early preclinical interest. SLUPP-332 is a research tool compound that has never been tested in humans. Cardarine was abandoned by its developers after it caused cancer in multiple animal studies. Presenting all four as a ready-to-use stack glosses over an enormous range of evidence quality and a serious safety red flag.
- Tesofensine: A monoamine reuptake inhibitor originally developed for Parkinson's. Astrup et al. (2008, The Lancet) found 0.5mg/day produced around 12.8 kg weight loss over 24 weeks, but it raised heart rate and blood pressure. No approved human use exists.
- 5-amino-1MQ: An NNMT inhibitor with one published mouse study (Neelakantan et al., 2019, Nature Communications) showing fat mass reduction. Zero human trials.
- SLUPP-332: A REV-ERB agonist studied in mice (Woldt et al., 2013, Nature Medicine). Shown to improve metabolic markers in rodents. No human data whatsoever.
- Cardarine (GW501516): A PPAR-delta agonist dropped by GlaxoSmithKline and Ligand Pharmaceuticals after causing rapid multi-organ cancer in rodent studies. Doering et al. (2014, Drug Testing and Analysis) flagged it as a doping concern. WADA banned it. Describing it as "the endurance king" without mentioning the carcinogenicity data is a serious omission.
What did they get wrong (or right)?
The claim that cardarine "makes every workout twice as effective" sidesteps the reason its own pharmaceutical developers walked away from it. That is not a minor detail to leave out. SLUPP-332 calling it a metabolic booster for human use is simply not supportable. It is a research chemical used in laboratory settings. Tesofensine does have meaningful human trial data, so the appetite suppression claim has a real basis, but framing it as safe and accessible ignores cardiovascular side effects documented in the same trials. The one thing he got directionally right is that 5-amino-1MQ targets a metabolic pathway with genuine scientific interest, but a single mouse study does not translate to "pure lipolysis" in humans. The conspiratorial framing, "they don't want you to know," does real harm because it discourages legitimate skepticism.
What should you actually know?
Three of these four compounds have never been tested in human clinical trials for fat loss. The one with the most human data, tesofensine, is not approved anywhere and carries cardiovascular risks. Cardarine is the most serious concern: it was shelved specifically because of carcinogenicity signals that appeared quickly in animal studies, not after years of use. Stacking compounds with different and poorly understood mechanisms is not "alignment," it is pharmacological experimentation with no safety data to guide dosing, interactions, or long-term effects. If you are looking for appetite control and metabolic support with an actual evidence base and regulatory oversight, GLP-1 receptor agonists like semaglutide and tirzepatide have extensive Phase 3 data and FDA approval. They are not the same as this stack and should not be conflated with it, but they represent what peer-reviewed, regulated fat loss intervention actually looks like in 2024.
The bottom line
This video is not a supplement stack review. It is four research chemicals, one of which has animal carcinogenicity data serious enough to end its pharmaceutical development, being presented as a personal optimization protocol. The framing is aspirational and the omissions are material. Viewers deserve to know the difference between a mouse study and a human trial, and between a compound that was studied and one that was abandoned for safety reasons.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 drugs and fat loss: does 'metabolic efficiency' hold up?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 drugs and fat loss: does 'metabolic efficiency' hold up? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The stack described combines a monoamine reuptake inhibitor (tesofensine), an NNMT inhibitor (5-amino-1MQ), a REV-ERB agonist (SLUPP-332), and a PPAR-delta agonist (cardarine), none of which are approved for human use and three of which lack any human clinical trial data.
FormBlends verdict
The stack described combines a monoamine reuptake inhibitor (tesofensine), an NNMT inhibitor (5-amino-1MQ), a REV-ERB agonist (SLUPP-332), and a PPAR-delta agonist (cardarine), none of which are approved for human use and three of which lack any human clinical trial data. Cardarine is of particular concern: its original pharmaceutical developers terminated development after rapid-onset carcinogenicity findings in multiple animal species. No regulatory body has approved any of these compounds for fat loss, and their combined use in humans has no published safety or pharmacokinetic data.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The stack described combines a monoamine reuptake inhibitor (tesofensine), an NNMT inhibitor (5-amino-1MQ), a REV-ERB agonist (SLUPP-332), and a PPAR-delta agonist (cardarine), none of which are approved for human use and three of which lack any human clinical trial data. Cardarine is of particular concern: its original pharmaceutical developers terminated development after rapid-onset carcinogenicity findings in multiple animal species. No regulatory body has approved any of these compounds for fat loss, and their combined use in humans has no published safety or pharmacokinetic data.
- Cardarine (GW501516) was dropped by GlaxoSmithKline after causing cancer in multiple organ systems in animal studies. WADA banned it in 2009. Its absence from shelves is a safety decision, not suppression.
- Tesofensine has the most robust human data of the four compounds, but Phase 2 trials (Astrup et al., 2008, The Lancet) documented heart rate increases and blood pressure elevation alongside weight loss.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Cardarine (GW501516) was dropped by GlaxoSmithKline after causing cancer in multiple organ systems in animal studies. WADA banned it in 2009. Its absence from shelves is a safety decision, not suppression.
- Tesofensine has the most robust human data of the four compounds, but Phase 2 trials (Astrup et al., 2008, The Lancet) documented heart rate increases and blood pressure elevation alongside weight loss.
- 5-amino-1MQ has exactly one published preclinical study in mice (Neelakantan et al., 2019, Nature Communications). No Phase 1 human safety trials have been published.
- SLUPP-332 is a laboratory research compound used to study circadian rhythm biology in rodents. It has never been administered to humans in a published clinical trial.
- Stacking four unapproved compounds with different receptor targets creates drug interaction and safety profiles that have never been studied. There is no dose-response or pharmacokinetic data for this combination.
- FDA-approved GLP-1 receptor agonists like semaglutide have been evaluated in trials involving tens of thousands of participants. That scale of evidence does not exist for any compound in this video.
- The conspiratorial framing 'they don't want you to know' is a rhetorical technique that actively discourages the skepticism viewers need most when evaluating unregulated compounds.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Tony Huge · TikTok creator
25.8K views on this video
For a long time, fat loss always came with tradeoffs for me. Low energy, muscle loss, or burnout. What finally worked was focusing on appetite control, metabolic efficiency, and endurance at the same time instead of relying on willpower alone. Once those pieces were aligned, fat loss felt smoother, workouts felt easier, and I stopped feeling like I was fighting my body every day. It completely changed how I approach getting lean. Disclaimer: This content reflects personal experience, not medica
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Tony Huge, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.